fda tirzepatide ruling 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these FDA says 'no clinical need'

Jacob Haiavy Updated on Jun 8, 2026

BPC-157 has anti-inflammatory properties, while GHK-Cu helps protect cells from damage caused by free radicals

Yes, and this is a conversation that does not happen often enough

Early clinical trials and large retrospective datasets suggest that semaglutide and tirzepatide can meaningfully reduce alcohol cravings and consumption for some people

As of 2025, an estimated 15.5 million Americans have used injectable weight loss medications, a category that has grown approximately 300% since 2021

The data presentations also signal that were, again, moving beyond just mean percent weight loss